Through a combination of new mechanistic insights, new targets and new understanding of complex biology, we have developed a platform technology that has broad applications across a range of diseases with potential to benefit patients all over the world.
The immune system consists of highly specialised cells that have evolved to detect, identify, and destroy pathogens and tumour cells that would otherwise do us harm. These immune cells are controlled by a fine balance of positive and negative signals transmitted via regulatory receptors on the cell surface.
Under normal conditions the negative signals prevent attack on the body's own cells and restore the system to a state of balance after a productive immune response. However, in auto-immune disease control is lost and a cascade of positive activating signals leads to destruction of healthy tissue.
MiroBio is developing therapeutic antibodies that can reapply the natural 'brakes', restoring control and preventing any further damage.
At MiroBio, we have the expertise to select optimal targets and to generate, and thoughtfully select, antibodies that activate and trigger immune receptors. When this mechanism is directed towards inhibitory (negative signalling) targets, they can dampen the overactive immune response seen in auto-immune diseases and restore balanced immune function, preventing further tissue damage.
We have a powerful, proprietary range of tools and techniques to discover, optimize, and develop these modulating antibodies, using our fundamental understanding of their mechanism based on the insights of MiroBio's founding scientists.
Diseases associated with overactive immune responses result in symptoms of inflammation and ultimately the damage and destruction of healthy tissue and organs. Current treatment involves broad immunosuppressants, which lack specificity, or antibodies against cytokines such as TNFα, IL6, and IL17, which do not target the underlying cause of disease and rarely restore long-term control.
MiroBio is focused on the development of more targeted therapeutics with a novel mechanism of action by utilizing our understanding of antibody signalling and by characterizing the immune response in patients. Through this biologically-driven approach we can specifically target the cells that driver disease and control their activity, leading to superior treatments of auto-immunity.